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Background: Several intracellular signaling pathways that are deregulated during 
hepatocarcinogenesis might constitute potential targets for hepatocellular carcinoma (HCC) 
therapy. The aim of this study was to test the potential synergic antitumor effect of salirasib and 
sorafenib in a diethylnitrosamine (DEN)-induced HCC model in rat. The hypothesis of tumor 
phenotype changes during treatment was also analyzed.
Materials and methods: DEN was administered to Wistar rats during 9 weeks to induce 
cirrhosis and liver cancer. After tumor development, rats were treated with intraperitoneal injec-
tions of dimethyl sulfoxide (DMSO), or salirasib, and/or with oral sorafenib 5 days/week, during 
4 weeks. At sacrifice, number and size of liver tumors as well as tumor burden were recorded, 
and all liver tumors were processed for histological and immunohistological analyses.
Results: Mortality rate was significantly higher in rats treated with salirasib and/or sorafenib than 
in the control group (P=0.001). Tumor burden was smaller in the treated group compared with 
the DMSO control group (P=0.044), but a synergistic effect of the two chemotherapies could 
not be observed. In 62.5% of rats (10/16) treated with salirasib and/or sorafenib, a cytokeratin-7 
and -19-positive hepatocholangiocellular carcinoma (HCC/CHC) was found vs 20% (5/25) 
developing such phenotype in the DMSO control group (P=0.018). Ki67 immunostaining showed 
significantly reduced tumor cell proliferation in treated rats (P=0.001), whereas apoptosis as 
assessed by caspase-3 activity in cell lysate was similar in all groups.
Conclusions: The addition of sorafenib to salirasib did not seem to provide any synergistic 
therapeutic effect in this study. Both chemotherapeutic agents, administered alone or in com-
bination, induced tumoral phenotypic changes in the majority of rats, a finding not associated 
with an increased tumor cell proliferation or decreased apoptosis. The rat model described in 
this work constitutes the first experimental tool generating putatively more aggressive combined 
HCC/CHC tumors following chemotherapy. Further work is required to better characterize this 
clinically relevant phenomenon.
Keywords: liver neoplasms, chemotherapy, disease management, liver transplantation
Introduction
Hepatocellular carcinoma (HCC) is fifth most common malignant tumor worldwide, 
and the second leading cause of cancer-related death.1,2 Surgical resection and liver 
transplantation offer encouraging results in patients with early stage HCC, with 
patient survival ranging from 40% to 80% at 5 years.3,4 Despite many advances in 
HCC management, the prognosis for intermediate and advanced stages remains poor, 
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due to a high recurrence rate following medical or surgical 
treatment. Moreover, phenotypic changes of the tumor lead-
ing to increased aggressivity were also observed following 
chemotherapy in HCC patients.5,6 The pathophysiology of 
HCC involves complex processes associating genetic and 
epigenetic changes, including several intracellular signaling 
pathways, not yet fully understood.7
This complexity probably explains the lack of therapeutic 
response when only one signaling pathway is targeted. 
Several combined therapies acting on more than one signal-
ing pathway have therefore been proposed. The aim of such 
strategies is to prevent the development of resistance to a 
single agent, as well as to improve the efficacy, putatively 
through apoptosis enhancement and inhibition of angiogen-
esis and cell proliferation. Both MAPK (Ras/Raf/MEK/ERK) 
and PI3k/Akt/mTOR pathways seem to play a key role in 
liver carcinogenesis in experimental models as well as in 
humans.7,8 In particular, the Ras pathway is almost always 
activated in human HCC; moreover, relatively recent studies 
have shown that overexpression of the Ras/MEK/ERK 
cascade is correlated with poorer survival of HCC patients.9,10 
Salirasib is a S-farnesyl cysteine analog that interferes with 
Ras membrane anchorage and inhibits the active GTP-bound 
Ras in various human cancer cell lines.11,12 The tumor preven-
tive effect of salirasib has already been demonstrated in a 
chemically induced HCC rodent model, by activating apop-
tosis and blocking hepatocyte proliferation.13 The efficacy 
of salirasib as a strong inhibitor of human HCC cell line 
proliferation was also observed in vitro.14 VEGF consti-
tutes a key stimulus for angiogenesis in highly vascularized 
tumors like HCC. Sorafenib is a multikinase inhibitor tar-
geting VEGF-receptor and PDGFR kinases as well as Raf. 
Its clinical effectiveness has already been demonstrated by 
the results of the SHARP multicentric trial in patients with 
advanced HCC.15
The aim of the present study was to test the antitumor 
effect of and tolerance to salirasib and sorafenib, alone or 
in combination at different doses in a diethylnitrosamine 
(DEN)-induced HCC model in rat. The hypothesis of changes 
in tumor phenotype following such chemotherapies, as 
observed in the clinical setting, was also analyzed in this 
experimental model.
Materials and methods
animals
Four-week-old male Wistar rats (mean body weight: 152 g, 
range: 101–170 g) were obtained from the Janvier Labs, 
Le Genest-St-Isle, France. Animals were housed in barrier 
facilities on a 12-hour light/dark cycle and kept in a temperature 
and humidity-controlled environment; standard food (Usine 
d’Alimentation Rationnelle, Villemoisson-sur-Orges, 
France) and water were supplied ad libitum. Animal care was 
provided in accordance with the guidelines for laboratory 
animals established by the Université Catholique de Louvain 
in accordance with European regulations and in conformity 
with ARRIVE guidelines. The study protocol was approved 
by the University Ethics Committee (2012UCLMD026).
cirrhosis and liver tumor induction
Animals (n=76) were acclimated for 2 weeks, then a solution 
of DEN (0.01%; Sigma Chemical Co., Saint Louis, MO, 
USA) was continuously administered via drinking water for 
9 weeks followed by a 3-week washout period. DEN concen-
tration was adapted weekly, according to the weight of the 
animals as previously described by us and others.16
A laparotomy was planned after a washout period 
of 3 weeks, in order to confirm cirrhotic evolution and 
liver tumor development. Thereafter, surviving animals 
were randomly assigned to one of six groups of treatment, 
as detailed in Table 1. Sorafenib (Nexavar, Bayer Scher-
ing Pharma AG, Berlin, Germany) and salirasib (S-trans-
trans-farnesylthiosalicyclic acid, Concordia Pharmaceuticals, 
Ft. Lauderdale, FL, USA) were diluted in 0.1% dimethyl 
sulfoxide (DMSO) to a final volume of 500 µL and daily 
administered, by gavage or intraperitoneal injections, 
respectively, 5 days per week during 4 weeks, under short 
sedation with isoflurane, using doses determined by the 
in vitro study described hereafter. DMSO (500 µL) was 
administered intraperitoneally with the same schedule in the 
control group (n=30).
in vitro study
FTO-2B cells (HCC rat line; Thermo Fisher Scientific, 
Waltham, MA, USA) were incubated in DMEM, supplemented 
Table 1 Details of treatment for each group of rats alive after 
development of chemically induced cirrhosis and liver cancer (n=67)
Group Number 
of rats
Dose Administration
DMsO  
(control group)
30 500 µl i.p.
salirasib 9 10 mg/kg i.p.
sorafenib 6 7.5 mg/kg gavage
sorafenib 6 15 mg/kg gavage
salirasib+sorafenib 8 10 mg/kg+7.5 mg/kg i.p.+gavage
salirasib+sorafenib 8 10 mg/kg+15 mg/kg i.p.+gavage
Abbreviations: DMsO, dimethyl sulfoxide; i.p., intraperitoneally.
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with DMSO or different concentrations of salirasib (50 and 
150 µM), alone or in combination with sorafenib (1, 2.5, 
and 5 µM), in order to define the effectiveness and toxicity 
of these molecules.17 Briefly, cell viability was evaluated 
48 hours later using a colorimetric WST-1 assay (Roche, 
Vilvoorde, Belgium), this method allows evaluation of the 
proportion of metabolically active cells, labeled by a higher 
optical density (absorbance) in spectroscopic analysis. 
IC50 values for each drug combination and dosage (value 
at which cell growth is inhibited by 50% compared with 
the control group) were calculated by nonlinear regression 
analysis using GraphPad Prism software (San Diego, CA, 
USA) (Figure 1).
histology and immunohistochemistry
All surviving rats were sacrificed 1 week after the end of the 
therapeutic phase (Figure 2). Rat and liver weight as well as 
number and diameter of all whitish liver nodules measuring 
more than 2 mm and visualized after slicing the liver every 
2 mm were recorded. Tumor burden was calculated accord-
ing to the WHO definition: length × width for each target 
lesion and sum of the value of each tumor.18 All suspicious 
liver lesions were resected and fixed overnight in 10% 
buffered formalin and embedded in paraffin; a specimen of 
each of all these lesions was also frozen for further analysis. 
Five-micrometer sections of formalin-fixed and paraffin-
embedded liver tumoral specimen were stained with H&E for 
conventional histology. HCC was diagnosed at conventional 
histology in presence of thick trabecular growth pattern 
composed of cells showing eosinophilic cytoplasm with 
irregular nucleus and distinct nucleoli. The diagnosis of com-
bined hepatocholangiocellular carcinoma (HCC/CHC) tumor 
was made if a glandular structure was clearly present.19 Immu-
nohistochemical staining was performed on deparaffinized 
4 µm tissue sections with the Dako Envision system (Dako 
Japan Co. Ltd, Kyoto, Japan). Mouse monoclonal antibodies 
against CK19 (dilution 1:200; Sigma), CK7 (dilution 1:50; 
Abcam, Cambridge, UK), alpha-fetoprotein (AFP) (dilution 
1:500; Abcam), and Ki67 (dilution 1:50; Abcam) were used. 
The two former permitted to confirm the biliary nature of 
the tumoral glandular proliferation, AFP the hepatocellular 
nature of the tumoral proliferation, and the latter used as an 
index of tumoral cell proliferation. Computer image analyses 
of immunostained sections for Ki67 were performed using 
Zeiss microscope coupled to an Axiocam camera (MR3, 
Carl Zeiss, Munich, Germany) and the AxioVision software 
(Zeiss). A morphometrical quantification was therefore done, 
leading to a mean percentage of labeled nuclei for each speci-
men of liver tissue.20 Calculation of the percentage of labeled 
nuclei by the specific antibody on slides was performed via 
a computer algorithm (Ki67 index).
apoptosis assessment
Apoptosis was assessed by fluorogenic activity assays of 
effector caspase-3 in cell lysates, using the Caspase-Glo® 
3/7 Assay (Promega Corporation, Fitchburg, WI, USA) as 
indicated by the manufacturer. Cell lysates were prepared 
according to the procedure as described previously.21
Figure 1 cellular viability as assessed by colorimetric WsT-1 assay (Y-axis: relative absorbance, determined at 450 nm) on cultured rat’s FTO-2B cells in vitro, submitted to 
DMsO (control group) and different concentrations of salirasib (50 and 150 µM) and sorafenib (1, 2.5, and 5 µM), alone or in combination.
Note: These data allowed extrapolation of ic50 value for the different doses of drugs (data not shown).
Abbreviation: DMsO, dimethyl sulfoxide.
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statistical analysis
Analysis was run using SPSS (version 25.0; IBM Corp., 
Armonk, NY, USA). All the quantitative variables were 
tested for normality with the Shapiro–Wilk test. Accordingly, 
all normality distributed variables were tested with Student’s 
t-test and the other ones with the Mann–Whitney U test. 
One-way ANOVA test was used to compare tumor burden 
in different groups of rats after randomization. Animal 
survival was analyzed with the Kaplan–Meier method and 
the log-rank test was used to compare survival between 
subgroups. The significance of statistical tests was taken at 
a P-value #0.05.
Results
impact of low and high doses of salirasib 
and sorafenib on cell viability of tumor 
cells in vitro
As shown in Figure 1, high doses of salirasib as single 
therapy did not seem to impact cellular viability, as assessed 
by WST-1 assay. By contrast, the combination of these two 
drugs clearly showed enhanced cytotoxicity when sorafenib 
concentration was increased, already with the low dose of 
salirasib (50 µM). Accordingly, a dose-dependent cyto-
toxic effect of sorafenib in combination with salirasib was 
suspected, and it was decided to include two subgroups of 
animals treated with low and high doses of sorafenib in the 
in vivo experiment.
Tumoral induction, mortality, and 
antitumor treatment outcome
Five of the 76 rats given DEN for 9 weeks died during the 
washout period of 3 weeks, leaving a study population 
of 71 animals at the end of the tumoral induction phase 
(Figure 2). As originally planned, exploratory laparotomy 
was performed at week 12, starting with 17 animals randomly 
selected. Macroscopic examination confirmed cirrhosis in 
100% of these animals as well as whitish tumoral nodules on 
the livers (Figure 3A). Laparotomy was poorly tolerated with 
an early (,24 hours) postsurgical mortality of 23.5% (4/17). 
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Figure 2 experimental design including tumoral induction with Den (during 9 weeks), assessment of tumor induction (week 12th), randomization to therapeutic groups 
(week 13th), mortality in each group, and sacrifice (week 18th).
Abbreviations: Den, diethylnitrosamine; DMsO, dimethyl sulfoxide.
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Figure 3 (A) Macroscopic appearance of dyschromic, whitish tumor (black arrows) developed on cirrhotic liver in rats given Den for 9 weeks and which died after 
exploratory laparotomy at week 12. (B) representative h&e section of hcc in rats that died after laparotomy, showing a trabecular pattern with nuclear atypia and absence 
of portal tract (low magnification, ×10).
Abbreviations: hcc, hepatocellular carcinoma; Den, diethylnitrosamine.
Given such unexpected high mortality rate and based on 
the development of cirrhosis and HCC tumors observed 
in all 17 laparotomized animals, the laparotomy was not 
performed in the remaining 54 rats. Moreover, postmortem 
histology of macroscopically identified tumors in the four 
rats that died after laparotomy confirmed HCC development 
(Figure 3B). It was therefore assumed that cirrhosis and 
HCC had likely developed in all rats before randomization. 
At week 13, surviving rats (n=67) were randomized into six 
groups, which received salirasib (10 mg/kg), sorafenib (7.5 or 
15 mg/kg), salirasib (10 mg/kg) combined with sorafenib 
(7.5 or 15 mg/kg), or DMSO in the control group, for a dura-
tion of 4 weeks, 5 days per week (Table 1).
An overall mortality rate of 38.8% (26/67) was observed 
at week 17, with only 41 of 67 animals alive at the end of the 
4-week therapeutic phase. Mortality was significantly higher 
in animals receiving chemotherapy (21/37) compared with 
the DMSO controls (5/30) (56.7% vs 16.6%, respectively, 
P=0.001). However, mortality did not differ in relation 
to the chemotherapeutic regimens (P=0.322), and deaths 
were homogenously distributed over the entire period 
of treatment.
In order to assess the efficacy of salirasib alone or in 
combination with sorafenib in our HCC-model, the number of 
suspect lesions (whitish nodules .2 mm) and tumor burden 
in all surviving animals (n=41) were evaluated at sacrifice. 
The mean number of tumors per liver was 7 (range: 4–14). 
The number of tumors in control and treated groups (irrespec-
tive of the chemotherapeutic regimen) was not statistically 
different (data not shown; P=0.213). Because the absolute 
number of tumors might only partially reflect the antitumor 
treatment response, we also determined the overall tumor 
burden, as defined in the Materials and methods section. 
Interestingly, tumor burden was significantly lower in 
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rats receiving chemotherapy than in DMSO control group 
(P=0.044), suggesting some response of HCC to the differ-
ent treatment regimens. However, no significant differences 
could be found between the different types of treatment 
(sorafenib alone at low or high doses, and salirasib alone or 
in combination with sorafenib) (Figure 4).
Pathological and immunohistological 
assessment of tumor lesions
All macroscopically suspect liver lesions were dissected 
at sacrifice and subjected to conventional histology (H&E 
staining). Histology revealed well-differentiated or mod-
erately differentiated pure HCC in 19 of the 25 (76%) 
surviving animals of the DMSO group. The histological 
diagnosis was confirmed by immunohistochemistry, since 
tumors only expressed AFP (Figure 5A and B), but neither 
CK7 nor CK19. In the six remaining DMSO rats, five had 
combined HCC/CHC tumor, with CK7 and CK19 positiv-
ity on immunostaining in at least one tumoral nodule; in 
the last DMSO animal, histology was suggestive of an 
angiosarcoma. By contrast, only a minority of animals (6/16) 
treated with salirasib and/or sorafenib showed a histologi-
cally and immunohistochemically proven pure HCC in all 
examined tumors. The proportion of HCC/CHC combined 
tumors was significantly higher in animals receiving chemo-
therapy than in controls (P=0.018). Indeed, 62.5% (10/16) 
presented at least two tumors that were either negative or 
weakly positive for AFP but strongly expressing CK7 and/
or CK19, highly suggestive of HCC/CHC mixed type tumor 
(Figure 5C–F).
assessment of the overall proliferation–
apoptosis balance in tumor nodules
The impact of chemotherapy on the apoptosis–proliferation 
balance in tumor nodules was also evaluated, aiming to ana-
lyze whether variations of this balance could at least partially 
explain the appearance of a different tumor phenotype. As a 
marker of cell proliferation, immunolabeling for Ki67 on 
tumoral and nontumoral tissue was performed in a total of 
28 animals, including treated (n=12) or untreated (DMSO 
control group, n=16) rats. In the control group, as well as in 
treated animals whatever the type of treatment, Ki67 index 
was higher in tumoral tissue compared with the surround-
ing nontumoral cirrhotic tissue (Figure 6). The comparison 
between treated (n=12) and untreated (n=16) tumors revealed 
a significantly lower Ki67 expression in the treated groups 
than in control group (Figure 7; P=0.001). A similar, but 
nonsignificant trend toward lower Ki67 expression was also 
found in nontumoral tissue of treated rats when compared 
with cirrhotic, nontumoral liver in DMSO group. These obser-
vations suggest an antiproliferative effect of chemotherapies 
mainly directed to tumor cells. Nevertheless, in treated ani-
mals, no significant difference in Ki67 expression could be 
found when pure HCC were compared with combined HCC/
CHC tumors (20.5% vs 16.8%; P=0.6). Caspase-3 activity 
was assessed as a surrogate marker for apoptosis in 22 animals 
(six in DMSO group, 16 in treated groups). A trend toward 
lower caspase-3 activity in tumoral and nontumoral tissues in 
the treated groups compared with tumoral and nontumoral tis-
sues in DMSO group was observed (Figure 8). However, the 
difference did not reach statistical significance (P=0.156).
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Figure 4 Median (range) values of tumor burden (Y-axis) at sacrifice. Tumor burden (assessed as length×width for each target lesion, and sum of the value of each tumor) 
was significantly decreased in treated rats compared with DMSO control group (P=0.044).
Abbreviation: DMsO, dimethyl sulfoxide.
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Figure 5 histology and immunohistochemistry of tumors.
Notes: (A) conventional histology (h&e) of pure hcc in DMsO rat, with thick trabecular growth pattern composed of tumor cells showing eosinophilic cytoplasm with 
irregular nuclear and distinct nucleoli, with massively positive aFP immunolabeling; (B) conventional histology (h&e) showing a mixed type hcc/chc in treated rat with two 
components; (C) thick trabecular/solid structure and (E) clearly glandular structures and positive cK-19 (D) and cK-7 (F) immunolabeling (×20 magnification). 
Abbreviations: aFP, alpha-fetoprotein; DMsO, dimethyl sulfoxide; hcc, hepatocellular carcinoma; hcc/chc, hepatocholangiocellular carcinoma.
Discussion
More than 80% of HCC develop on cirrhotic liver, and 
accordingly, a curative approach must take into account the 
cancer as well as the underlying liver disease. This explains 
why partial surgical resection is not considered as an option 
in the majority of patients who present with advanced liver 
impairment at the time of tumor diagnosis. In order to better 
stratify therapeutic strategies, preclinical models coupling 
cirrhosis and HCC should be designed and used. Several 
models of chemically induced HCC on liver fibrosis and 
cirrhosis have already been published.22 The alkylating agent 
DEN is frequently used in rodents as it induces cirrhosis as 
well as liver tumors that are molecularly similar to human 
HCC with poor prognosis.23 This model has already been used 
by our group, DEN being administered orally during 6 weeks 
or intraperitoneally during various time intervals.24,25 In the 
present study, DEN was administered orally for 9 weeks, 
inducing cirrhosis and tumor development in all animals, as 
confirmed by macroscopic, histological, and immunohisto-
logical analysis.
Current knowledge on molecular mechanisms involved 
in hepatic carcinogenesis has led to the development of tar-
geted therapies, specific to several pathogenic pathways.26 
In particular, VEGF-related tumor angiogenesis, as well as 
proliferation and cell survival dependent on m-TOR and 
Ras signaling pathways, may constitute targets of interest 
for treatment in HCC. Sorafenib represents the only therapy 
currently approved as first-line VEGF and Ras inhibitor in 
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Figure 6 Representative immunohistochemistry of Ki67 in tumoral and nontumoral tissue of DMSO control group and in treated animals (magnification ×20). 
Abbreviation: DMsO, dimethyl sulfoxide.
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patients with nonresectable HCC, but with only a modest 
benefit in terms of patient survival.10
Conceptually, targeted combination therapies should 
reduce the size of tumors to make them resectable or to 
consider liver transplantation within Milan or San Francisco 
criteria.3,27 Several combination chemotherapies have been 
proposed in Phase III drug trial.28 Nevertheless, the results 
obtained up to now with combined chemotherapies remain 
unsatisfactory in terms of tumor control and patient survival, 
with, in addition, a significant toxicity.29 Our group has previ-
ously shown the preventive effect of salirasib in the develop-
ment of tumor foci in DEN-induced HCC model.8 Moreover, 
Charette et al14 showed the antitumoral efficacy of salirasib 
in a xenograft model where Hep G2 cell line derived from 
human hepatoblastoma was implanted subcutaneously in 
athymic mice.9 However, evidence upon efficacy of salirasib 
once a tumor has developed (curative purpose) is lacking. 
The choice to combine sorafenib and salirasib in the pres-
ent study comes from the clinical use of the former and the 
interesting experimental results obtained so far by Charette 
et al for the latter. Accordingly, our study aimed to assess 
both toxicity and antitumoral efficacy of such combination 
administered at different doses after tumor development. 
In the present experiment, a very high mortality rate was 
found in all treated groups (56.7%), which could be related 
to a poor tolerance to these compounds in cirrhotic livers 
with a high tumor burden. However, no evidence of increased 
toxicity expressed by creatinine, bilirubin, and transaminases 
was demonstrated when comparing DMSO and treated rats 
(data not shown). From an antitumoral efficiency perspective, 
this study showed significantly decreased tumor burden in 
the treated groups, irrespective of the treatment, compared 
with the control group (P=0.044). However, our data could 
not confirm a synergistic therapeutic effect of salirasib and 
sorafenib, but this observation should be definitively con-
firmed in a larger cohort of animals. The doses of salirasib 
and sorafenib used in our experiment were chosen on the 
basis of other published works and after having carried 
out an in vitro study with FTO-2B hepatoma cells of rats. 
Based on this study and data in the literature, we suspected 
that the use of lower doses of salirasib (eg, 10 mg/kg) and 
sorafenib (eg, 7.5 mg/kg) would no longer be effective. 
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Figure 7 Ki67 labeling index after immunohistochemical staining Ki67 expression 
was significantly higher in tumoral than in nontumoral tissue in DMSO group as well 
as in treated animals (P,0.001).
Notes: A statistically significant difference was also found between tumoral tissue in 
DMsO group (n=16) compared with treated tumor (n=12) (P=0.001). +Mean values.
Abbreviation: DMsO, dimethyl sulfoxide.
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However, we cannot formally exclude that in vivo in this rat 
model, using smaller doses of these two molecules may still 
have a cytotoxic antitumor effect with a better tolerance.
Nevertheless, this regimen should be mentioned with 
extreme caution and might be proposed only if other alterna-
tives may not be applied.
Intriguingly, a significant percentage of surviving rats 
treated with salirasib and/or sorafenib showed tumoral pheno-
typic changes, as evidenced by the development of combined 
HCC/CHC in 62.5% of treated animals vs 20% in the control/
DMSO group (P=0.018). Mixed HCC/CHC was defined 
according to the 2010 WHO classification, as tumor showing 
small monotonous glands with antler-like intersection patterns 
and hepatocytes with pronounced nuclei.30 In addition, immu-
nohistochemistry confirmed the histological diagnosis, because 
immunostaining for CK7 and CK19 was positive in these 
instances. This phenomenon of phenotypic tumoral change has 
recently been reported by several authors after locoregional 
treatment, such as transarterial chemoembolization (TACE), 
administered in patients with HCC on cirrhosis.5,6 Preliminary 
clinical data from our group confirmed that combined HCC/
CHC were found on the native liver specimen at transplantation 
in 14% of patients (6/43) receiving at least two locoregional 
treatments prior to liver transplantation, while a phenotypic 
tumoral change was never found in patients transplanted 
without TACE (0/18). Beside its therapeutic effect, these data 
suggest that TACE may also induce phenotypic changes in 
HCC similar to those observed in our animals after targeted 
therapy. Therefore, a phenotypic change of tumors under high 
selection pressure (eg, TACE or combined targeted therapies) 
could potentially trigger some tumor escape mechanism, with 
the selection of cellular variants resistant to the treatment 
administered. The mechanism involved in such tumor escape 
process may involve increased cell proliferation leading to 
increased mutation rate, enhanced angiogenesis, or reduced 
apoptosis, but it remain poorly understood. In the present study, 
there was no relation between the phenotypic change and 
increased cellular proliferation in the mixed tumor type. Ki67 
expression was significantly lower in tumor nodules of treated 
animals (regardless of the tumor phenotype) compared with 
HCC tumors in the DMSO group. This contributes to reinforce 
the initial observation of an antitumor, antiproliferative effect 
of the treatment regimens. Our results on caspase-3 activity 
also showed that apoptosis was not significantly increased 
after administration of salirasib and/or sorafenib. We cannot 
formally exclude that a potential resistance to apoptosis could 
have contributed to the tumoral phenotypic change. An addi-
tional explanation might be epithelial-to-mesenchymal transi-
tion (EMT). From a histological point of view, we had no clear 
sign of a morphological change of tumor cells into fusiform 
cells, which is typical in EMT. EMT is also characterized by a 
loss of E-cadherin and gain of mesenchymal markers such as 
vimentin. In our study, E-cadherin and vimentin immunohis-
tochemistry did not produce any convincing results in favor of 
EMT (data not shown). Clearly, additional mechanistic studies 
(eg, analyzing angiogenesis) are needed to better understand 
this tumor escape process.
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Figure 8 caspase-3 activity in tumoral and nontumoral tissue.
Notes: Caspase-3 activity was lower in tumoral and nontumoral tissues in the treated groups; as shown, a slight but nonsignificant reduction in caspase-3 activity was found 
in tumor of animals after administration of salirasib and/or sorafenib (n=16) compared with DMsO control group (n=6) (P=0.154; ns).
Abbreviations: DMSO, dimethyl sulfoxide; NS, not significant.
The development of mixed tumors with a cholangiocellular 
component could have important clinical implications in HCC 
management. Such HCC/CHC constitutes a rare form of 
primary liver cancer (0.4%–14%) and is clinically associated 
with poor prognosis.31,32 Vascular invasion, regional organ 
involvement, nodal and distant metastases seem to play a role 
in tumor aggressiveness.32 These recent observations could lead 
to modify the therapeutic algorithm used until now for HCC 
in humans. In particular, a tumoral downstaging by iterative 
TACE in patients with HCC awaiting liver transplantation 
could theoretically lead to the development of mixed HCC/
CHC tumors, with a poorer prognosis. Clinicians should remain 
cautious before administrating iterative TACE and targeted 
therapies to patients potentially eligible for liver transplanta-
tion, unless further studies are available to validate the efficacy 
of these treatments in terms of better prognosis and survival.
In conclusion, the present study provided the first preclini-
cal model of targeted chemotherapy-induced change of HCC 
phenotype and advocated caution before using iteratively this 
type of therapy in HCC patients. Furthermore, this model 
could be useful to further study the mechanistic phenomena 
underlying phenotypic changes in tumors exposed to a high 
selection pressure and to define the useful ways that might 
help to counteract this process.
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